Companion Diagnostics Pioneers Explore A Variety Of Business Models
This article was originally published in The Gray Sheet
Executive Summary
Stakeholders are hoping the regulatory environment for personalized medicine will brighten in the Obama administration, but uncertainty persists about the business case for drug-diagnostics partnerships